Next we analyzed the correlation between ERBB2 and various clinico‐pathological characteristics, including gender, age (<55 and ≥55 years), TNM stage, risk factors (HBV infection, HCV infection, nonalcoholic fatty liver disease), and alcohol abuse, using the TCGA cohort (Table S1). Here, ERBB2 is linked to metabolic dysfunction-associated steatotic liver disease.